Quest Diagnostics (DGX) SVP Mark Delaney Buys 34 Shares

What Happened
Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics (DGX), reported a small acquisition on the Form 4. On 2026-07-22 he acquired 34 shares at $206.81 per share, a total value of approximately $7,031. The transaction is an acquisition (purchase) rather than a sale.

Key Details

• Transaction date: 2026-07-22; Form 4 filed: 2026-07-27 (filing marked late — "L").
• Price and amount: 34 shares at $206.81 each — total ≈ $7,031.
• Shares owned after transaction: Not specified in the provided details.
• Footnotes: F2 indicates these shares were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and were eligible for deferred reporting under Rule 16a-6; the insider chose to report early. F1 denotes restricted share units in the filer’s holdings (not necessarily related to this specific line item).
• Accession: 0001022079-26-000079 (for reference).

Context
This appears to be a routine dividend reinvestment purchase rather than a market-timed buy; such DRIP purchases are common and typically reflect reinvested dividends. The late filing ("L") reduces the timeliness of the disclosure but does not change the transaction facts. Small, routine purchases like this are factual signals of ownership accumulation but should be weighed alongside broader insider activity and company fundamentals.